The estimated Net Worth of Claire Fraser is at least $7.34 millió dollars as of 28 August 2023. Ms. Fraser owns over 848 units of Becton Dickinson & Co stock worth over $5,049,574 and over the last 18 years she sold BDX stock worth over $1,939,964. In addition, she makes $351,224 as Independent Director at Becton Dickinson & Co.
Claire has made over 8 trades of the Becton Dickinson & Co stock since 2019, according to the Form 4 filled with the SEC. Most recently she sold 848 units of BDX stock worth $238,848 on 28 August 2023.
The largest trade she's ever made was selling 1,500 units of Becton Dickinson & Co stock on 11 February 2020 worth over $388,080. On average, Claire trades about 173 units every 34 days since 2007. As of 28 August 2023 she still owns at least 21,608 units of Becton Dickinson & Co stock.
You can see the complete history of Ms. Fraser stock trades at the bottom of the page.
Claire M. Fraser Ph.D serves as Independent Director of the Company. Since 2007, she has been Director of the Institute for Genome Sciences and a Professor of Medicine at the University of Maryland School of Medicine in Baltimore, Maryland. From 1998 to 2007, she served as President and Director of The Institute for Genomic Research, a not-for-profit center dedicated to deciphering and analyzing genomes. Dr. Fraser is the President-Elect of the American Association for the Advancement of Science (AAAS), and also serves on the Board of AAAS and Ohana Biosciences Inc. Dr. Fraser is a prominent scientist with a strong background in infectious diseases and molecular diagnostics, including the development of novel diagnostics and vaccines. She also brings considerable managerial experience in her field.
As the Independent Director of Becton Dickinson & Co, the total compensation of Claire Fraser at Becton Dickinson & Co is $351,224. There are 16 executives at Becton Dickinson & Co getting paid more, with Vincent Forlenza having the highest compensation of $16,014,600.
Claire Fraser is 64, she's been the Independent Director of Becton Dickinson & Co since 2006. There are 8 older and 25 younger executives at Becton Dickinson & Co. The oldest executive at Becton Dickinson & Co. is Marshall Larsen, 71, who is the Lead Independent Director.
Claire's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 22 years, insiders at Becton Dickinson & Co have traded over $106,782,599 worth of Becton Dickinson & Co stock and bought 23,860 units worth $1,771,828 . The most active insiders traders include Edward J Ludwig, William M Brown és Vincent A Forlenza. On average, Becton Dickinson & Co executives and independent directors trade stock every 20 days with the average trade being worth of $4,349,205. The most recent stock trade was executed by Roland Goette on 14 August 2024, trading 5,295 units of BDX stock currently worth $701,799.
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.
Becton Dickinson & Co executives and other stock owners filed with the SEC include: